Loading annual review details
Cardinal Health, Inc. (CAH)FY2026 investor yearly review
Across FY2026, management emphasized broad enterprise execution with Pharma strength and accelerating Specialty capabilities, while the GMPD turnaround progressed through simplification and cost optimization. Q4 closed the year with strong cash flow and raised forward outlook, though management continued to monitor tariff dynamics and input-cost uncertainty.
Overall investor read
Resilient growth with execution and integration upside
Management consistently pointed to strong demand and disciplined cost and integration execution across segments.
Primary financial signal
$5.17B operating cash flow
Full-year cash generation materially supported continued capital returns alongside business investment.
Primary call signal
Raised FY2026 EPS and cash flow outlook again
Q1 and Q2 raised guidance, and Q3/Q4 further increased non-GAAP EPS and adjusted free cash flow expectations.
Headline results and cash generation that anchored management’s strategy narrative.
Revenue
Down year over year; management emphasized demand strength and mix.
Gross margin
Gross margin reported at 4.0% with mix and acquisitions cited.
Operating margin
Operating margin stayed low; execution and mix were the focus.
Net income
Net income down sharply year over year; management highlighted non-GAAP durability.
Diluted EPS
EPS down year over year; guidance revisions were discussed as progress.
Operating cash flow
Operating cash flow increased strongly, supporting capital returns.
Free cash flow
Free cash flow rose materially, reinforcing cash generation quality.
Management’s FY2026 arc moved from a strong demand-led start into specialty scale-up, with the GMPD turnaround progressing through Q4-end resilience.
Specialty growth
Across Q1 to Q4, management tied the specialty narrative to Specialty Alliance progress and MSO platform expansion, culminating in Solaris integration “on track” and added urology capabilities. Investors repeatedly asked about M&A and ramp expectations, and management kept emphasizing integration execution and platform value creation.
Quarter-by-quarter materiality and tone for annual transcript themes.
Scroll horizontally to see more columns.
| Theme | Q1 | Q2 | Q3 | Q4 | Next monitor |
|---|---|---|---|---|---|
| Specialty Alliance and MSO integration to drive profit growth | Positive Solaris acquisition progress and Specialty Alliance expansion drove optimism | Positive |
Management’s year-end message was that disciplined execution and specialty scale increased profitability, while tariffs, input costs, and revenue mix mechanics continued to create uncertainty.
Management described Solaris as a catalyst within Specialty Alliance and discussed integration as on track across the year. Q2 treated the deal as officially completed in November, and Q3/Q4 reiterated progress and synergy realization actions.
Management repeatedly connected Cardinal Health brand growth and “simplification and cost optimization” to improved operational health. Q2 cited positive Cardinal Health branded performance, and Q4 described steady growth plus automation-driven improvements.
FY2026 began with a demand-led beat and outlook raise, then progressed to specialty scale-up and GMPD turnaround execution before ending with guidance reaffirmation and cash-flow strength.
Profitability pressure but strong cash generation
FY2026 moved from early-year execution and guidance raises toward specialty scale-up and integration payoff, while GMPD tariff volatility and Pharma revenue mix mechanics remained key variables through Q4.
Management said Q1 exceeded expectations with profit growth led by Pharma and Specialty, while other growth businesses accelerated. Guidance was raised for EPS, alongside updates on Solaris closing and GMPD tariff phasing.
Read earnings transcriptWith Solaris completed in November, management emphasized momentum and broad-based profit growth across segments. EPS and segment profit outlooks moved higher, while management addressed Q2 tariff normalization and comparison cadence into the back half.
Management provided directional and range guidance for EPS and adjusted free cash flow, with multiple raises during the year.
$9.65 to $9.85; $3B to $3.5B
Revenue $64.01B; EPS $1.7; Other $4.53B
Q1 management raised EPS and adjusted free cash flow ranges, and the year-end cash outcome suggests credibility, though EPS actuals are not directly comparable from provided values.
$10.15 to $10.35; Adjusted free cash flow $3B to $3.5B
EPS $1.7; Other $4.53B
In Q2, management raised FY2026 EPS range again and reiterated robust adjusted free cash flow; evidence in the year-end cash metrics supports confidence.
Forward-looking monitoring points centered on specialty execution, tariff-driven GMPD variability, and the persistence of Pharma demand and revenue mix dynamics.
Specialty profit growth expectations depend on integrating Solaris into the Specialty Alliance platform.
Watch integration milestones and management’s statements on synergy realization and added specialty practice capabilities.
Tariff mechanics can swing GMPD profitability and complicate forecasting around refunds and replacements.
Track management’s GMPD segment profit guidance cadence and updates on IEPA refund clarity versus ongoing tariff costs.
Core distribution execution
Management described continued strong pharmaceutical demand across categories while explaining revenue-line volatility as GLP-1 growth and IRA/WAC-related impacts offset each other. Q3 highlighted the complexity of revenue mix versus profit strength, but management stayed consistent: assume strong demand without “outsized” surprises.
Operational turnaround
Throughout the year, management described improvement plan initiatives yielding Cardinal Health brand growth, with cost optimization and simplification as recurring drivers. Tariff impacts created quarter-to-quarter noise: management discussed Q2/Q3 tariff phasing and later called out Q4’s nonrecurring IEEPA refund while still monitoring ongoing tariff replacement and input costs.
Capital allocation
Management consistently anchored the year on cash flow management—highlighting adjusted free cash flow generation and disciplined capital deployment. Q1 emphasized free cash flow and share repurchase progress; Q2 and Q3 added leverage and CapEx discipline context; Q4 culminated with large full-year adjusted free cash flow and a higher share repurchase authorization.
Solaris completion in November added momentum to MSO platform
Positive Solaris integration on track; Specialty growth accelerated above 20% |
Positive Specialty extended momentum; enterprise guidance supported ‘more of the same’ |
| Track Specialty revenue >$50B messaging, Solaris practice/ramp updates, and MSO synergy delivery cadence. |
| Pharma demand strength translating through GLP-1 and WAC mechanics | Positive Robust pharma demand and GLP-1 contribution supported guidance raise | Positive Management maintained strong demand assumptions amid revenue mix headwinds | Mixed GLP-1 uplift offset IRA/WAC downdraft; profit held up | Mixed Guidance assumed strong demand, excluding outsized demand surprises | Monitor GLP-1 revenue growth commentary, WAC/IRA stated headwinds, and Pharma profit guidance cadence. |
| GMPD improvement plan progress with tariffs driving volatility | Mixed Brand growth continued; tariff costs expected to step up | Mixed Cardinal Health brand grew; tariffs partially offset improvement | Negative Tariffs created adverse GMPD profit impact; refund timing uncertain | Mixed IEEPA refund benefit boosted reported results; ongoing tariff monitoring continued | Watch GMPD segment profit guide, tariff refund clarity, and commodity/fuel input-cost commentary. |
| Cash generation, disciplined CapEx, and sustained share repurchases | Positive Adjusted free cash flow and buyback progress reinforced capital discipline | Positive CapEx pacing and leverage within target range supported flexibility | Positive Free cash flow and repurchases continued; EPS guidance rose again | Positive Full-year adjusted free cash flow and higher buyback authorization | Monitor adjusted free cash flow guidance ranges, leverage ratio targets, and CapEx execution vs plan. |
| Other growth businesses compounding via ADS, Theranostics, and logistics | Positive ADS integration synergies; Theranostics and OptiFreight outperformance | Positive Other segment delivered strong profit growth; ADS integration advanced | Positive Integration execution and Theranostics pipeline supported Other growth | Positive Integration synergies and Theranostics expansion sustained Other momentum | Monitor Theranostics growth commentary, at-Home integration milestones, and OptiFreight technology adoption. |
| Customer service levels at/near record supporting utilization and durability | Positive Network capacity expansion and service focus supported demand translation | Positive Service levels benchmarked; investments supported product availability | Positive Record high service levels despite winter storm complexity | Positive At-Home reliability metrics highlighted; fill rate near 99% | Track service-level KPIs management cites (fill rate/on-time departures) and inventory/capacity initiatives. |
Management highlighted adjusted free cash flow and disciplined capital allocation, with buybacks reaching milestones in Q1/Q2 and full-year completion in Q3/Q4. Q4 also increased share repurchase authority, signaling confidence in cash generation.
Across quarters, management emphasized investments in automation and network capacity supporting product availability and service. Q3 referenced record-high service levels under winter storm complexity, and Q4 noted near-99% fill rate and best on-time departures.
Management discussed tariff impacts as a moving variable: expected step-ups in Q2, adverse GMPD profit impacts in Q3, and a Q4 nonrecurring IEEPA refund benefit. Even with clarity improving, timing and longer-term tariff replacements remained monitored.
Management described offsetting effects in Pharma revenue—GLP-1 growth lifting results while WAC-related adjustments and IRA dynamics pressured revenue line. Q3 explicitly framed profit strength as resilient despite revenue mix variability.
While management emphasized on-track integration, it also pointed to phased onboarding and systems work, especially for at-Home and specialty distribution ramping. The year’s narrative repeatedly tied outcomes to flawless integration and maintaining service levels.
Management discussed commodity and fuel-related pressures impacting distribution and GMPD costs, while describing mitigation and flexibility actions. In Q4, management highlighted sensitivity levels and monitoring tied to guidance range positioning.
Scroll horizontally to see more columns.
| Quarter | Revenue | YoY revenue growth | Diluted EPS | Gross margin | Investor read |
|---|---|---|---|---|---|
| Q1Sep-25 | $64.01B | 6.4% | $1.88 | 3.6% | Strong start: upside came from demand across Pharma, early MSO/Specialty contributions, and disciplined cost execution. |
| Q2Dec-25 | $65.44B | 2.2% | $1.97 | 3.4% | Momentum broadened: profit growth in all five segments and raised full-year EPS with confidence for Q3/Q4. |
| Q3Mar-26 | $60.94B | -6.9% | $1.69 | 4.1% | Profits and cash flow stayed resilient; GMPD tariff volatility was the clearest quarterly swing factor. |
| Q4Q4 FY2026 | - | - | - | 0.0% | Year ended with strong cash flow and raised buyback authorization; FY2027 guidance framed ‘strong demand, not outsized’. |
Management raised full-year non-GAAP EPS and adjusted free cash flow guidance, citing strong core performance and operational execution. At the same time, it highlighted GMPD profit pressure from tariffs and uncertainty around refund timing.
Read earnings transcriptManagement framed Q4 as closing FY2026 on broad enterprise demand and execution, supported by strong adjusted free cash flow and liquidity. It also used Q4 IEEPA tariff refund clarity and reiterated FY2027 planning assumptions for Pharma and GMPD.
Read earnings transcript$10.70 to $10.80; $3.3B to $3.7B
EPS $1.7; Other $4.53B
Q3 guidance raises for non-GAAP EPS and adjusted free cash flow were supported by strong operating execution; the full-year cash outcome aligns with that credibility.
Revenue line volatility from policy-related pricing mechanics can affect margins and comparability despite stable demand.
Monitor GLP-1 growth commentary, WAC-related offset explanations, and how Pharma profit growth tracks revenue normalization.
Raised capital return posture relies on sustaining cash conversion from working capital efficiency and operational discipline.
Follow management’s adjusted free cash flow ranges and working capital commentary alongside CapEx execution and repurchase timing.
Management repeatedly linked service levels to demand translation, customer stickiness, and execution durability.
Track quoted KPIs like fill rate/on-time departures and any service-level commentary during weather or operational complexity.
Dafinchi